The United States Food And Drug Administration (FDA) has approved a new cystic fibrosis (CF) drug combination (tezacaftor/ivacaftor) that can be used in patients who have two copies of F508del mutation (the most common CF mutation), and in patients who have at least a single copy of one of 26 specified mutations. Using this combination can treat more number of CF patients than compared to an earlier combination.
